Abiologics

Abiologics is at the forefront of biotechnology, leveraging artificial intelligence and chemistry to develop a new class of supranatural and programmable biologics. These advanced therapeutics are designed to treat a wide range of diseases more effectively than traditional methods. The company primarily serves patients and healthcare providers, operating within the biopharmaceutical market. Abiologics employs a business model focused on research and development, creating proprietary biologics that are then licensed or sold to pharmaceutical companies. Revenue is generated through licensing agreements, partnerships, and direct sales of their innovative therapeutics. The company's multidisciplinary team combines expertise in machine learning and biology to systematically expand the toolkit for future medicines.

Keywords: AI-driven, supranatural biologics, programmable therapeutics, biopharmaceutical, disease treatment, innovative medicines, healthcare, biotechnology, R&D, Flagship Pioneering.